# Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

> **NCT03126071** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Raltitrexed
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03126071
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-15
- **Primary completion:** 2022-08-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126071, "Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03126071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*